
Xencor (XNCR) Stock Forecast & Price Target
Xencor (XNCR) Analyst Ratings
Bulls say
The financial outlook for Xencor Inc is optimistic due to the anticipated revenue growth from existing partnerships and a promising pipeline of antibody product candidates, particularly XmAb819, which has shown initial success and clear clinical benefit. The company’s technology platform and collaborations enhance its valuation, suggesting that market opportunities in both oncology and autoimmune indications could drive substantial future revenues. Furthermore, recent share price volatility is viewed as a strategic entry point for investors, with a strong risk/reward profile anticipated based on de-risking mechanisms and potential market successes yet to be fully realized in Xencor's stock valuation.
Bears say
Xencor Inc's negative outlook is influenced by the potential for limited durability and safety issues associated with its pipeline candidate XmAb819, which could lead to a significant decline in share value. The company's recent setbacks, including the discontinuation of AGS-16C3F due to lack of efficacy against existing treatments and the elevated rates of cytokine release syndrome (CRS) in clinical trials, highlight significant operational risks. Additionally, ongoing challenges in achieving regulatory approval, meeting sales expectations, and securing expected royalties from partnerships further complicate the company's financial trajectory.
This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.
Xencor (XNCR) Analyst Forecast & Price Prediction
Start investing in Xencor (XNCR)
Order type
Buy in
Order amount
Est. shares
0 shares